Fortress Biotech (FBIOP) Stock Analysis & Winston Score

Fortress Biotech is a pharmaceutical company that develops and sells medicines, mostly for rare diseases and cancer. It works by building or acquiring smaller drug companies — called "partner companies" — and helping them grow, while also selling a handful of approved products directly. Its main customers are patients and hospitals in the United States. Fortress makes money in two ways: selling its own approved drugs and collecting royalties, fees, and equity stakes from its partner companies as those companies advance their own drugs. It operates primarily in the US and has a portfolio of over a dozen partner companies at various stages of development. The 64.5% gross margin on its commercial products shows decent pricing power, but the deeply negative operating margin reflects heavy spending on research and development across its broad pipeline. The biggest risk is that most of its partner companies are still in clinical trials, meaning Fortress needs continued access to capital to fund operations until more drugs reach the market.